J Korean Diabetes > Volume 19(1); 2018 > Article
The Journal of Korean Diabetes 2018;19(1):35-40.
DOI: https://doi.org/10.4093/jkd.2018.19.1.35    Published online April 13, 2018.
제2형 당뇨병 약제치료 지침 2017 개정안: Glucagon-Like Peptide-1 수용체작용제
김현진
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.
Hyun Jin Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. kimhj43@cnuh.co.kr
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy, which was a change from the previous guideline that recommended them only as a combination therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) have demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RAs may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
Key Words: Cardiovascular diseases, Diabetes mellitus, Glucagon-like peptide-1 receptor agonist, Hypoglycemia, Obesity, Practice guideline


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer